Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Metagenomi Therapeutics, Inc. (MGX)

Metagenomi director Brian Thomas resigns; shareholders elect two Class II directors

Neutral Impact 2 of 5 leadership Written later

Metagenomi director Brian C. Thomas resigned from the board effective June 9, 2026, with the company saying the resignation involved no disagreement on its operations, policies or practices. At the same day's annual meeting, shareholders re-elected... elected Juergen Eckhardt and Eric Bjerkholt as Class II directors and ratified PricewaterhouseCoopers LLP as auditor for 2026.

Key points

  • Brian C. Thomas resigned from the Board effective June 9, 2026; the filing states no disagreement with the company.
  • Juergen Eckhardt received 7,296,718 votes for and 1,436,882 withheld; Eric Bjerkholt received 8,251,289 for and 482,311 withheld.
  • Shareholders ratified PricewaterhouseCoopers LLP for fiscal 2026 with 18,483,295 for, 51,847 against and 581,065 abstentions.
  • Shares present or represented were 19,116,207 of 37,647,057 outstanding and entitled to vote, establishing a quorum.

The filing

CompanyMetagenomi Therapeutics, Inc. (MGX)
Form8-K, current report
Filed with the SECJun 9, 2026, 6:11 PM ET
Accession number0001193125-26-264392

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.